By Nancy Lapid
(Reuters) -Bariatric surgeries led to about five-times more weight loss than weekly injections of popular GLP-1 drugs, according to data from a real-world comparison study presented on Tuesday at the American Society for Metabolic and Bariatric Surgery scientific meeting in Washington.
“Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year,” study leader Dr. Avery Brown of NYU Langone Health said in a statement.
Researchers reviewed records of 38,545 patients who were prescribed injectable semaglutide or tirzepatide between 2018 and 2024 and 12,540 patients who underwent bariatric surgery during the same period. Everyone started the study with a body mass index of at least 35, which is considered severe obesity.
Semaglutide is the main ingredient in Novo Nordisk’s Wegovy and Ozempic, while tirzepatide is the main ingredient in Eli Lilly’s Zepbound and Mounjaro.
At three years after undergoing sleeve gastrectomy or gastric bypass or starting the drugs, patients who underwent surgery had lost on average 24% of their starting weight, compared to about 5% for similar patients who used the drugs for at least six months and about 7% for those who took them for a year.
Brown noted that as many as 70% of GLP-1 patients may discontinue treatment within one year.
“While both patient groups lose weight, metabolic and bariatric surgery is much more effective and durable,” ASMBS President Dr. Ann M. Rogers, who was not involved in the study, said in a statement.
“Those who get insufficient weight loss with GLP-1s or have challenges complying with treatment due to side effects or costs, should consider bariatric surgery as an option, or even in combination,” she said.
NEW BLOOD TEST MAY REDUCE LIVER TRANSPLANT FAILURES
An experimental blood test can help surgeons catch and identify problems with newly transplanted livers at early stages, researchers say.
It’s not unusual for transplanted organs and recipients’ nearby tissues to sustain damage during the transplantation process. Hints of problems will show up later in routine blood tests, but identifying the precise site of the damage often requires costly imaging studies and surgical biopsies, according to a report published on Tuesday in Nature Communications.
The new test works by picking up DNA fragments left behind in the blood by dying cells. The chemical signatures on these DNA fragments can be used to identify the original cell type and where it came from, with precise detail, the researchers found.
If you can determine which part of the liver is injured – for example, the bile ducts, or the blood vessels – “you could provide a more personalized treatment approach that leads to better care for the patient,” study leader Dr. Alexander Kroemer of MedStar Georgetown University Hospital in Washington, DC said in a statement.
In addition to being faster and less invasive than a traditional biopsy, the blood test is also potentially more accurate, because biopsies only sample a few spots in the liver and might miss the site of the problem, he added.
Georgetown has filed patent applications on the technology, and the research team is seeking partners to commercialize the test.
DIABETES PRECURSOR SHOWS UP ON MUSCLE ULTRASOUND
Ultrasound exams of thigh or shoulder muscles can detect insulin resistance at its earliest stages, researchers reported in the Journal of Ultrasound in Medicine.
“We perform a large number of shoulder ultrasounds and noticed that many patients’ muscles appear unusually bright,” study leader Dr. Steve Soliman of the University of Michigan said in a statement.
His team discovered in earlier studies that most of these patients have type 2 diabetes. But some had bright muscles on ultrasound even with no signs of diabetes or prediabetes.
Subsequently, upon short-term follow-up, these patients often also developed prediabetes or type 2 diabetes.
To test the potential for noninvasive muscle ultrasound as a predictive tool for detecting the development of pre- or type 2 diabetes – potentially earlier than current methods – the researchers performed muscle ultrasounds on 25 patients who were also being evaluated for insulin resistance.
Although muscle ultrasound could detect insulin resistance and impaired insulin sensitivity, in this small study the level of brightness was not directly correlated with the degree of the condition. The researchers are recruiting more participants to continue the analysis.
The exact reason why muscle brightness on ultrasound might indicate insulin resistance is less clear than the finding that it does, the researchers said.
“Clinicians increasingly use these point-of-care and handheld ultrasound devices, sometimes called ‘the stethoscope of the future,’ for rapid diagnosis of various conditions,” Soliman said.
“A medical assistant or clinician with little to no training could easily use this device on a patient’s upper arm or thigh, as routinely as checking weight or blood pressure, and potentially flag patients as ‘high risk’ or ‘low risk’ for further testing.”
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; editing by Bill Berkrot)
Comments